化疗对有乳腺癌的绝经前妇女卵巢功能的影响
Olaiya Popoola1, Mohammad Habeebu2, Akeem Adeniji3
1Department of Radiation and Clinical Oncology, Marcelle Ruth Cancer Center, Lagos 101241, Nigeria.
Medicine international
|November 12, 2025
概括
化疗在年轻的乳腺癌患者中显著损害卵巢功能,改变了诸如雌激素和抗穆勒激素等关键激素水平. 这些对生育能力的负面影响在治疗后至少持续六个月.
科学领域:
- 生殖内分泌学 生殖内分泌学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 众所周知,化疗会损害卵巢功能,可能导致不孕,特别是在年轻女性中.
- 化疗对绝经前乳腺癌患者卵巢储备的具体影响需要进一步研究.
研究的目的:
- 评估化疗对被诊断患有乳腺癌的绝经前妇女的卵巢功能和储备的影响.
- 评估化疗治疗后关键生殖激素水平的变化.
主要方法:
- 招募了82名绝经前女性乳腺癌患者,计划接受化疗.
- 在基线,化疗后3个月和6个月,测量了雌激素,卵泡刺激激素 (FSH) 和抗穆勒激素 (AMH) 的血度.
- 使用直接免疫酶色度测量方法进行激素测定.
主要成果:
- 观察到血雌激素和AMH水平的显著降低.
- 在化疗后记录了FSH水平的显著增加.
- 在30岁以上的患者中观察到月经不规则或停止;影响持续了6个月,并且独立于化疗方案.
结论:
- 乳腺癌的化疗会对卵巢功能产生不利影响,这是由雌激素,FSH和AMH水平的显著变化表明的.
- 这些有害的卵巢影响在治疗后至少持续六个月.
- 临床医生必须向乳腺癌患者就潜在的生育问题提供咨询,以改善长期的生活质量.
相关概念视频
Oogenesis
68.9K
In human women, oogenesis produces one mature egg cell or ovum for every precursor cell that enters meiosis. This process differs in two unique ways from the equivalent procedure of spermatogenesis in males. First, meiotic divisions during oogenesis are asymmetric, meaning that a large oocyte (containing most of the cytoplasm) and minor polar body are produced as a result of meiosis I, and again following meiosis II. Since only oocytes will go on to form embryos if fertilized, this unequal...
68.9K
Cancer Therapies
9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
581
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
581
Menopause
3.5K
Menopause, a natural biological process marking the end of a woman's fertility, typically occurs between the fifth and sixth decade of life. This phase is characterized by the exhaustion of the ovarian follicle pool, leading to less responsive ovaries despite the high levels of Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH). The consequential decrease in estrogen production results in symptoms like hot flashes, heavy sweating, headaches, hair loss, muscle pains, vaginal...
3.5K
Hormonal Control of the Ovarian Cycle
6.4K
The ovarian cycle is meticulously regulated by the hypothalamic-pituitary-gonadal axis. This cycle orchestrates the release of a mature oocyte, essential for reproduction.
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...
6.4K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
543
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
543


